- Home
- KC vs MLYS Comparison
KC vs MLYS Comparison
Compare KC & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KC | MLYS |
|---|---|---|
| Founded | 2012 | 2019 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 3.1B |
| IPO Year | 2020 | 2023 |
Fundamental Metrics
Financial Performance| Metric | KC | MLYS |
|---|---|---|
| Price | $10.31 | $36.34 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 7 |
| Target Price | $17.50 | ★ $47.33 |
| AVG Volume (30 Days) | 952.0K | ★ 1.5M |
| Earning Date | 11-19-2025 | 02-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,268,313,014.00 | N/A |
| Revenue This Year | $25.92 | N/A |
| Revenue Next Year | $17.44 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 24.11 | N/A |
| 52 Week Low | $9.12 | $8.24 |
| 52 Week High | $22.26 | $47.65 |
Technical Indicators
Market Signals| Indicator | KC | MLYS |
|---|---|---|
| Relative Strength Index (RSI) | 32.56 | 40.25 |
| Support Level | $10.56 | $36.50 |
| Resistance Level | $11.49 | $37.75 |
| Average True Range (ATR) | 0.33 | 1.57 |
| MACD | -0.04 | 0.01 |
| Stochastic Oscillator | 2.70 | 28.02 |
Price Performance
Historical ComparisonAbout KC Kingsoft Cloud Holdings Limited
Kingsoft Cloud Holdings Ltd is an independent cloud service provider in China. It provides integrated cloud-based services including cloud computing, storage, and delivery. Its products and services are Security, Database, Data Analysis, Networking, and others. Its solutions are medical, government affairs, finance, media, education, gaming, Vehicle solutions, and others.
About MLYS Mineralys Therapeutics Inc.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.